(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
Completed
Blueprint Medicines Corporation
Phase 1
2015-08-01
This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety,
tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of
avapritinib (formerly BLU-285), administered orally (PO), in adult patients with unresectable
GIST or other relapsed or refractory solid tumors. The study consists of 2 parts, a
dose-escalation part (Part 1) and an expansion part (Part 2).
(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
Active, not recruiting
Blueprint Medicines Corporation
Phase 1
2016-03-10
This is a Phase 1, open-label, dose-escalation study designed to evaluate the safety,
tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of
avapritinib (also known as BLU-285), administered orally (PO), in adult patients with
advanced systemic mastocytosis and other relapsed or refractory myeloid malignancies. The
study consists of 2 parts, a dose-escalation part (Part 1) and an expansion part (Part 2).
Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma
Completed
Fred Hutchinson Cancer Research Center
Phase 1
2016-12-15
This is a feasibility study in patients with localized or metastatic soft tissue sarcoma
undergoing surgery to determine how sarcoma in situ responds to injected microdoses of
anti-cancer therapeutics.
Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma
Completed
Northwell Health
Phase 1
2016-12-15
This is a feasibility study in patients with localized or metastatic soft tissue sarcoma
undergoing surgery to determine how sarcoma in situ responds to injected microdoses of
anti-cancer therapeutics.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
